Stockreport

Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations

Protara Therapeutics, Inc.  (TARA) 
PDF TARA-002 demonstrated compelling efficacy and was generally well-tolerated Enrollment in additional cohorts underway with initial results expected in 1H’25 NEW YOR [Read more]